Premium
Cutaneous angiosarcoma: a novel therapy with liposomal doxorubicin?
Author(s) -
Ockenfels Hans M.,
Brockmeyer Norbert H.,
Hengge Ulrich,
Goos Manfred
Publication year - 1996
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1996.tb00138.x
Subject(s) - medicine , doxorubicin , angiosarcoma , sarcoma , chemotherapy , liposome , radiation therapy , oncology , surgery , pathology , materials science , nanotechnology
The case of a 65 year old patient with a cutaneous angiosarcoma of the head and facial skin is reported. In contrast to preceding chemo‐and radiation therapies which did not induce any tumor regression, our treatment with liposomal doxorubicin HCL (Doxil®) caused considerable tumor regression. This therapy had to be stopped because of accumulated toxic side effects after multiple chemotherapies. The therapy with liposomal doxorubicin is known to yield good results in the therapy of Aids‐related Kaposi's sarcoma and is usually well tolerated. We assume that liposomal doxorubicin could be an effective chemotherapy compared to the conventional and in most cases only palliative therapies.